Versuchen GOLD - Frei
CDSCO flags batches of cough syrup 'Besto-Cof' as spurious
Business Standard
|October 25, 2025
The Central Drug Standards Control Organisation (CDSCO) has flagged select batches of one cough syrup as spurious, and listed 112 other drugs and formulations as not of standard quality (NSQ) in its routine surveillance for September 2025.
-
The central drug regulator said it had found a purported spurious sample of a cough syrup named Besto-Cof (Dry Cough Formula) from a state lab in Chhattisgarh as a part of its routing checks.
While the regulator has not disclosed the name of the manufacturer of the spurious syrup, it said that the actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been made by them, and that it is a spurious drug.
A drug is generally considered spurious when manufactured by unauthorised producers using brand names owned by other companies.
Diese Geschichte stammt aus der October 25, 2025-Ausgabe von Business Standard.
Abonnieren Sie Magzter GOLD, um auf Tausende kuratierter Premium-Geschichten und über 9.000 Zeitschriften und Zeitungen zuzugreifen.
Sie sind bereits Abonnent? Anmelden
WEITERE GESCHICHTEN VON Business Standard
Business Standard
A broken model
China is unwilling to implement the reforms needed
2 mins
March 10, 2026
Business Standard
Excise policy changes earnings positive for listed liquor majors
Various states have released their new excise policies and the changes could be potentially positive for the liquor industry.
3 mins
March 10, 2026
Business Standard
Hike in pump prices unlikely for now even as Brent tests $120/bbl
State OMCs ‘well-positioned’ to absorb impact; experts flag surge in oil import bill
3 mins
March 10, 2026
Business Standard
Conflict and tariffs dim the shine of Surat diamonds
With the war in West Asia upending global trade, the first part of a series examines how the global diamond hub is grappling with the raging crisis and also tariff uncertainty, even as lab-grown stones reshape the industry
3 mins
March 10, 2026
Business Standard
Missing half in India's growth puzzle
Female labour participation just 42%, among lowest in G20: Axis Bank study
3 mins
March 10, 2026
Business Standard
ECB volumes may grow 25-30% to $65 bn in FY27: Citibank executive
The overseas fundraising pipeline of Indian corporates through loans and bonds appears robust in the upcoming financial year (FY27), aided by a pick-up in capacity utilisation that could eventually spur private capex.
2 mins
March 10, 2026
Business Standard
Flipkart's holding firm back home after Press Note 3 nod for Tencent
Walmart-backed ecommerce firm may target listing in 2026 end or 2027
1 mins
March 10, 2026
Business Standard
A clear derating
Markets risk underperformance if we don’t regain our growth credentials
5 mins
March 10, 2026
Business Standard
Impact of rising crude oil prices on inflation won't be substantial: FM
The impact of the ongoing geopolitical clashes in West Asia and rising global crude oil prices on inflation is not estimated to be substantial at this point, given that India’s inflation is near the lower bound, Finance Minister Nirmala Sitharaman told Parliament on Monday.
2 mins
March 10, 2026
Business Standard
Mkts sink again, volatility surges
Indian equity markets slumped to their lowest levels in over 10 months on Monday after a sharp spike in crude oil prices rattled investors, stoking fears that a fresh bout of higher inflation could erode corporate earnings and slow economic growth.
2 mins
March 10, 2026
Listen
Translate
Change font size